MYOVのチャート
MYOVの企業情報
| symbol | MYOV |
|---|---|
| 会社名 | Myovant Sciences Ltd （MYOVANT SCIENCES） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix which is an oral once-daily small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids endometriosis-associated pain and advanced prostate cancer. The Company is developing MVT-602 an oligopeptide kisspeptin agonist for the treatment of female infertility. マイオバント・サイエンシズはバミュ―ダ諸島籍のバイオ医薬品企業。臨床段階で、主に女性特有の疾患と前立腺がんに対する治療薬の開発・商業化に従事する。同社パイプライン「Relugolix」は子宮筋腫、子宮内膜症、前立腺がんを治療する経口薬。また、「RVT-602」は女性の不妊症治療に利用される。本社はハミルトン。 Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder. |
| 本社所在地 | Suite 1 3rd Floor 11-12 St. James's Square London SW1Y 4LB GBR |
| 代表者氏名 | Myrtle Stephens Potter |
| 代表者役職名 | Chairman of the Board |
| 電話番号 | +44 1824-8101 |
| 設立年月日 | 42401 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 86人 |
| url | www.myovant.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） -240.29900 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 1730.65800 |
| 売上高 | （百万ドル） 0.00000 |
| 企業価値(EV) | （百万ドル） 1646.33100 |
| 当期純利益 | （百万ドル） -245.74100 |
| 決算概要 | BRIEF: For the nine months ended 31 December 2018 Myovant Sciences Ltd revenues was not reported. Net loss increased from $95M to $198.5M. Higher net loss reflects Research and development - Balancing increase from $74M to $158.3M (expense) General and administrative - Balancing increase of 87% to $21.2M (expense) Interest expense increase from $904K to $4.8M (expense). |
MYOVのテクニカル分析
MYOVのニュース
Sumitovant Buys Myovant 2023/03/10 16:47:03 The Middle Market
Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal valued at $1.7 billion.
1.39B Reasons To Be Bullish On Myovant Sciences Stock 2023/03/10 15:03:10 Benzinga
Sumitomo Chemical Co Ltd , 10% Owner at Myovant Sciences (NYSE: MYOV ), reported a large insider buy on March 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Ltd purchased 51,599,200 shares of Myovant Sciences. The total transaction amounted to $1,393,178,400. Myovant Sciences shares are trading up 0.06% at $27.0 at the time of this writing on Friday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily … Full story available on Benzinga.com
Myovant Sciences earnings missed by $0.14, revenue fell short of estimates By Investing.com 2023/01/27 02:08:00 Investing.com
Myovant Sciences earnings missed by $0.14, revenue fell short of estimates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M 2023/01/26 21:27:46 Seeking Alpha
Myovant Sciences press release (MYOV): Q3 GAAP EPS of -$0.56 beats by $0.08.Revenue of $100.23M (+84.1% Y/Y) misses by $2.13M.Cash, cash equivalents, marketable securities, and…
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 2023/01/26 21:05:00 GlobeNewswire
BASEL, Switzerland, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.
Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer 2022/04/04 15:08:00 Kwhen Finance
Myovant Sciences Ltd. (NYSE: MYOV) Has Succeeded In Generating Interest In 2022, The Stock Is Down -12.33% Year-To-Date 2022/03/26 13:00:00 Marketing Sentinel
Myovant Sciences Ltd. (NYSE:MYOV)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 2.74. At the close of trading, the stock’s price was $13.65, to imply a decrease of -5.01% or -$0.72 in intraday trading. The MYOV share’s 52-week high remains $27.43, putting it -100.95% down since that … Myovant Sciences Ltd. (NYSE: MYOV) Has Succeeded In Generating Interest In 2022, The Stock Is Down -12.33% Year-To-Date Read More »
Myovant secures European recommendation for prostate cancer therapy 2022/02/25 15:05:50 Seeking Alpha
Commercial-stage pharma company, Myovant Sciences <> announced Friday that an expert panel of the European Medicines Agency ((EMA)) issued a positive opinion on Orgovyx for…
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript 2022/01/26 20:18:06 Seeking Alpha
Myovant Sciences GAAP EPS of -$0.68 misses by $0.07, revenue of $54.4M in-line (NYSE:MYOV) 2022/01/26 11:56:04 Seeking Alpha
Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.68 misses by $0.07.Revenue of $54.4M (+3842.0% Y/Y) in-line.
Myovant secures European recommendation for prostate cancer therapy 2022/02/25 15:05:50 Seeking Alpha
Commercial-stage pharma company, Myovant Sciences <> announced Friday that an expert panel of the European Medicines Agency ((EMA)) issued a positive opinion on Orgovyx for…
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript 2022/01/26 20:18:06 Seeking Alpha
Myovant Sciences GAAP EPS of -$0.68 misses by $0.07, revenue of $54.4M in-line (NYSE:MYOV) 2022/01/26 11:56:04 Seeking Alpha
Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.68 misses by $0.07.Revenue of $54.4M (+3842.0% Y/Y) in-line.